411 related articles for article (PubMed ID: 27199119)
1. A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.
Broughton KM; Li J; Sarmah E; Warren CM; Lin YH; Henze MP; Sanchez-Freire V; Solaro RJ; Russell B
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H107-17. PubMed ID: 27199119
[TBL] [Abstract][Full Text] [Related]
2. Troponin destabilization impairs sarcomere-cytoskeleton interactions in iPSC-derived cardiomyocytes from dilated cardiomyopathy patients.
Dai Y; Amenov A; Ignatyeva N; Koschinski A; Xu H; Soong PL; Tiburcy M; Linke WA; Zaccolo M; Hasenfuss G; Zimmermann WH; Ebert A
Sci Rep; 2020 Jan; 10(1):209. PubMed ID: 31937807
[TBL] [Abstract][Full Text] [Related]
3. Differential responses of induced pluripotent stem cell-derived cardiomyocytes to anisotropic strain depends on disease status.
Chun YW; Voyles DE; Rath R; Hofmeister LH; Boire TC; Wilcox H; Lee JH; Bellan LM; Hong CC; Sung HJ
J Biomech; 2015 Nov; 48(14):3890-6. PubMed ID: 26476764
[TBL] [Abstract][Full Text] [Related]
4. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures.
Ting S; Chen A; Reuveny S; Oh S
Stem Cell Res; 2014 Sep; 13(2):202-13. PubMed ID: 25043964
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.
Wu H; Lee J; Vincent LG; Wang Q; Gu M; Lan F; Churko JM; Sallam KI; Matsa E; Sharma A; Gold JD; Engler AJ; Xiang YK; Bers DM; Wu JC
Cell Stem Cell; 2015 Jul; 17(1):89-100. PubMed ID: 26095046
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca
Halas M; Langa P; Warren CM; Goldspink PH; Wolska BM; Solaro RJ
Mol Pharmacol; 2022 May; 101(5):286-299. PubMed ID: 35236770
[TBL] [Abstract][Full Text] [Related]
7. Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.
Perea-Gil I; Seeger T; Bruyneel AAN; Termglinchan V; Monte E; Lim EW; Vadgama N; Furihata T; Gavidia AA; Arthur Ataam J; Bharucha N; Martinez-Amador N; Ameen M; Nair P; Serrano R; Kaur B; Feyen DAM; Diecke S; Snyder MP; Metallo CM; Mercola M; Karakikes I
Eur Heart J; 2022 Sep; 43(36):3477-3489. PubMed ID: 35728000
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial polymer matrices enhance in vitro maturation of human induced pluripotent stem cell-derived cardiomyocytes.
Chun YW; Balikov DA; Feaster TK; Williams CH; Sheng CC; Lee JB; Boire TC; Neely MD; Bellan LM; Ess KC; Bowman AB; Sung HJ; Hong CC
Biomaterials; 2015 Oct; 67():52-64. PubMed ID: 26204225
[TBL] [Abstract][Full Text] [Related]
9. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.
Sun N; Yazawa M; Liu J; Han L; Sanchez-Freire V; Abilez OJ; Navarrete EG; Hu S; Wang L; Lee A; Pavlovic A; Lin S; Chen R; Hajjar RJ; Snyder MP; Dolmetsch RE; Butte MJ; Ashley EA; Longaker MT; Robbins RC; Wu JC
Sci Transl Med; 2012 Apr; 4(130):130ra47. PubMed ID: 22517884
[TBL] [Abstract][Full Text] [Related]
11. SarcTrack.
Toepfer CN; Sharma A; Cicconet M; Garfinkel AC; Mücke M; Neyazi M; Willcox JAL; Agarwal R; Schmid M; Rao J; Ewoldt J; Pourquié O; Chopra A; Chen CS; Seidman JG; Seidman CE
Circ Res; 2019 Apr; 124(8):1172-1183. PubMed ID: 30700234
[TBL] [Abstract][Full Text] [Related]
12. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
[TBL] [Abstract][Full Text] [Related]
13. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
[TBL] [Abstract][Full Text] [Related]
14. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
Kampourakis T; Zhang X; Sun YB; Irving M
J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
16. In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes.
Yu T; Miyagawa S; Miki K; Saito A; Fukushima S; Higuchi T; Kawamura M; Kawamura T; Ito E; Kawaguchi N; Sawa Y; Matsuura N
Circ J; 2013; 77(5):1297-306. PubMed ID: 23392122
[TBL] [Abstract][Full Text] [Related]
17. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
[TBL] [Abstract][Full Text] [Related]
18. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
19. Small molecule-mediated refolding and activation of myosin motor function.
Radke MB; Taft MH; Stapel B; Hilfiker-Kleiner D; Preller M; Manstein DJ
Elife; 2014 Feb; 3():e01603. PubMed ID: 24520162
[TBL] [Abstract][Full Text] [Related]
20. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
Malik FI; Hartman JJ; Elias KA; Morgan BP; Rodriguez H; Brejc K; Anderson RL; Sueoka SH; Lee KH; Finer JT; Sakowicz R; Baliga R; Cox DR; Garard M; Godinez G; Kawas R; Kraynack E; Lenzi D; Lu PP; Muci A; Niu C; Qian X; Pierce DW; Pokrovskii M; Suehiro I; Sylvester S; Tochimoto T; Valdez C; Wang W; Katori T; Kass DA; Shen YT; Vatner SF; Morgans DJ
Science; 2011 Mar; 331(6023):1439-43. PubMed ID: 21415352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
